Evaluation the expression of Sp1 and Par3 in urinary bladder carcinoma

Document Type : Original Article

Authors

1 Pathology department, zagazig univeristy, faculty of medicine,Zagazig. Egypt

2 Clinical oncology zagazig university , faculty of medicine,Zagazig. Egypt

3 Clinical oncology, Zagazig university, faculty of medicine,Zagazig. Egypt

4 urology department, zagazig univeristy, faculty of medicine, Zagazig. Egypt

5 Department of general surgery faculty of medicine Zagzig university

6 pathology department. Zagazig university. faculty of medicine,Zagazig . Egypt

7 pathology,faculty of medicine,Zagazig univeristy,Egypt

Abstract

Abstract

Background: Bladder carcinoma is the second most common cause of death among all genitourinary tumors. Tumor recurrence, multifocality and metastasis are main causes of related mortality The primary objective of the present study is to evaluate the expression of Sp1 and Par3 in urinary bladder carcinoma and to investigate their correlation with clinicopathological characteristics and patient survival

Patients and Methods: This prospective cohort study included 50 urothelial carcinoma cases investigated for immunohistochemical expressions of Sp1 and Par3 followed them for five years or until death. The expression of markers in all tissue samples was assessed, analyzed, and correlated with clinical-pathological parameters and outcomes.

Results: The high expression of Sp1, and low expression of Par3 was significantly associated with poor clinicopathological characteristics and unfavourable overall survival.

Conclusion: The results suggested that Sp1 and Par3 may have roles in modulation of tumor invasion. Sp1 and Par3 may serve as valuable prognostic markers or therapeutic targets for urothelial carcinoma.

Keywords

Main Subjects

Zagazig University Medical Journal

Articles in Press, Accepted Manuscript
Available Online from 03 June 2024

Files

Share

How to cite

Statistics